Immunotherapy in COVID-19: why, who, and when?

Pratik Sinha; Carolyn S. Calfee

doi:10.1016/S2213-2600(21)00232-0

Immunotherapy in COVID-19: why, who, and when?

Pratik Sinha, Carolyn S. Calfee

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	549-551
Number of pages	3
Journal	The Lancet Respiratory Medicine
Volume	9
Issue number	6
DOIs	https://doi.org/10.1016/S2213-2600(21)00232-0
State	Published - Jun 2021

Access to Document

10.1016/S2213-2600(21)00232-0

Cite this

@article{283cef916a8c40c688a51ce62ada8625,

title = "Immunotherapy in COVID-19: why, who, and when?",

author = "Pratik Sinha and Calfee, {Carolyn S.}",

note = "Funding Information: PS declares no competing interests. CSC has received grant funding from the US National Institutes of Health (HL140026), US Food and Drug Administration, Roche-Genentech, Quantum Leap Healthcare Collaborative, and Bayer Pharmaceuticals, and has served as a consultant to Vasomune, Quark, and Gen1e Life Sciences.",

year = "2021",

month = jun,

doi = "10.1016/S2213-2600(21)00232-0",

language = "English",

volume = "9",

pages = "549--551",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

number = "6",

}

TY - JOUR

T1 - Immunotherapy in COVID-19

T2 - why, who, and when?

AU - Sinha, Pratik

AU - Calfee, Carolyn S.

N1 - Funding Information: PS declares no competing interests. CSC has received grant funding from the US National Institutes of Health (HL140026), US Food and Drug Administration, Roche-Genentech, Quantum Leap Healthcare Collaborative, and Bayer Pharmaceuticals, and has served as a consultant to Vasomune, Quark, and Gen1e Life Sciences.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85107113873&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(21)00232-0

DO - 10.1016/S2213-2600(21)00232-0

M3 - Comment/debate

C2 - 34015326

AN - SCOPUS:85107113873

VL - 9

SP - 549

EP - 551

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 6

ER -

Immunotherapy in COVID-19: why, who, and when?

Access to Document

Other files and links

Cite this